ClinicalTrials.gg
RecruitingNCT02587741CORRECTUpdated Oct 27, 2015

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

An Early Phase 1 interventional study of Metformin and Lantus in Diabetic Retinopathy, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-10-27.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Diabetic Retinopathy with a site in China — 27 open to participants now, 28 under way, 2 of them phase 3. Diabetic Retinopathy · China.

Planned enrollment
6th of 56
600 · median 139
Started
2015
with 4 others
Phase 1
4 of 85
3 open now
Primary completion
2023-07
later than 0 of 27 live
Registered
11th of 85
by date

Among the 85 studies in Diabetic Retinopathy with a site in China, this one is the 6th largest by planned enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2015, is one of 4 in phase 1, reaches primary completion later than 0 of the 27 other live ones, and was the 11th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

27 of the 85 studies in Diabetic Retinopathy with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Diabetic Retinopathy with a site in China, or all of them as a file.
02

Study summary

Diabetic retinopathy (DR) is an important cause of blindness.

Read the detailed description

Diabetic retinopathy (DR) is an important cause of blindness, and its development of an irreversible process. DR is not only the overall progress and the level of blood sugar, and blood glucose fluctuations more closely, is the key to a smooth hypoglycemic delay DR progression.Diabetes control and complication trail(DCCT) study shows that even though glycemic control was no significant difference in blood glucose fluctuations ,DR also have a significant difference. In this study, three different glucose-lowering program for: (A) a single oral anti-diabetic drugs, (B) basal insulin and oral anti-diabetic drugs, (C) premixed insulin and oral anti-diabetic drugs for comparison. Focus on the stability and the impact of these three programs hypoglycemic long-term prognosis of the DR, and thus affect the molecular mechanisms of DR-based exploration of glucose fluctuations, to optimize blood glucose solutions, lower blood sugar steady, slow progression of DR ultimate clinical purposes.

The multi-center study is to cooperate, enrolled 600 cases of type 2 diabetes, observe the effects of different solutions on blood sugar glucose fluctuations and retinopathy, a total of 5 years of follow-up. This will be the first at home and abroad to compare the incidence of hypoglycemic effect programs on DR large multi-center, randomized, controlled clinical studies, clinical practice will optimize the treatment of type 2 diabetes theoretical and evidence-based medicine.

03

Conditions studied

  • Diabetic Retinopathy

Keywords

  • type 2 diabetes mellitus
  • Diabetic Retinopathy
  • glucose fluctuation
  • oxidative stress
  • Insulin
  • Oral drugs
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged 30-65;
  2. diagnosed to be type 2 diabetes in accordance with the WHO diagnostic criteria in 1999 .
  3. diabetes duration for 5 years or less;
  4. the glycosylated () is higher than or equal to7.0% ;
  5. (BMI) 20-35 kg/m2;
  6. fluorescein fundus angiography (FFA) showed no diabetic retinopathy;
  7. women of childbearing-age have plan for 5 years plan;

Exclusion criteria

Exclusion Criteria:

  1. pregnant or lactating women;
  2. diabetes autoantibodies (GAD) antibodies positive;
  3. occurred state of diabetic ketoacidosis, diabetes, high permeability, diabetes lactic acidosis within a half years ;
  4. (AST), alanine aminotransferase (ALT) 2.5 times higher than normal ceiling, and/or serum creatinine (Cr) or 133 umol/l (1.5 mg/dl);
  5. disease history which can affect determination of ;
  6. have received a coronary angioplasty, coronary artery stent implantation, coronary artery bypass surgery, there was myocardial infarction, unstable angina, and clinical significance of abnormal ecg, cerebrovascular accident, or .
  7. psychiatric patients;
  8. any eye eyesight \< 0.1 patients (WHO blind eye disease: keratitis, need serious cataract surgery, glaucoma, uveitis, high myopia shaft > 26.5 mm, history of ocular trauma;Other ophthalmology medical history: the central vein occlusion, branch vein occlusion, wet sex senile macular degeneration, etc.;
  9. in eye surgery history, history of cataract surgery, and three months; Other serious diseases, the researchers think that don't fit into the patients
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    oral drugs

    oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard,added to 500mg tid→1000mg bid.if metformin reach the biggest dosage,added gliclazide modified release tablets,from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target,add acarbose 50mg tid

    Drug: Metformin

  • Experimental
    lantus

    basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm(at 8am if patients are night workers),add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.

    Drug: Lantus

  • Experimental
    Novomix30

    premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .

    Drug: Novomix30

Interventions

  • start with metformin,from 500mg bid,if metformin reach the biggest dosage,added gliclazide modified release tablets,afterthat,add acarbose

    Also known as: gliclazide modified release tablets, acarbose

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    started with insulin glargine 0.2 u/kg subcutaneous injection ,add dosage if glucose dose not reach the target.after that,you can add oral drugs(like oral drug group)

    Also known as: Metformin, gliclazide modified release tablets, acarbose

  • DrugNovomix30

    started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs

    Also known as: Metformin, gliclazide modified release tablets, acarbose

06

What researchers measure

Primary outcomes

  1. The incidence of diabetic retinopathy

    5-year incidence rate of diabetic retinopathy(%)

    Time frame: 5years

Secondary outcomes

  1. cardiovascular events

    myocardial infarction, angina,or cardiac insufficiency with other causes

    Time frame: 5 years

  2. renal failure

    use urinary protein excretion rate(%) evaluate clinical course of diabetic nephropathy

    Time frame: 5years

  3. glucose fluctuation

    we use continuous glucose monitoring system(CGMS),made by Medtronic company USA,and assess within-day blood glucose excursions,Daytime blood sugar stability and the stability of postprandial blood glucose,including Standard Deviation Of Blood Glucose(SDBG)in mmol/L, largest amplitude of glycemic excursions(LAGE)in mmol/L, mean amplitude of glycemic excursions(MAGE) in mmol/L,low glycemic index(LBMI),coefficient variation fasting glucose parameters,Mean Of Daily Differences(MODD)in mmol/L.

    Time frame: every one year in 5years

  4. oxidative stress

    Glyoxalase 1(GLO-1)in pg/ml,Advanced glycation end products(AGEs)in pg/ml,Soluble Receptor for advanced glycation end products(sRAGE)in pg/ml.

    Time frame: every one year in 5 years

Other outcomes

  1. Metabolic indices

    Fasting blood glucose(FBG)in mmol/L, postprandial blood glucose(PBG)in mmol/L, glycosylated hemoglobin(GHbA1c)in percentage.total cholesterol(TC), low density lipoprotein(LDL) and high density lipoprotein(HDL)in mmol/L.

    Time frame: every three months in 5 years

07

Study locations

1 of 1 sites recruiting
  • the third affiliated hospital of Sun yet-san university
    Guangzhou, Guangdong 510000, China
    Recruiting
08

References and documents

Publications

  • Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):179-83. doi: 10.1080/09286580701396720. PubMed 17896294 ↗
  • Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):552-63. doi: 10.1001/archopht.122.4.552. PubMed 15078674 ↗
  • Fischbacher CM, Bhopal R, Unwin N, Walker M, White M, Alberti KG. Maternal transmission of type 2 diabetes varies by ethnic group: cross-sectional survey of Europeans and South Asians. Diabetes Care. 2001 Sep;24(9):1685-6. doi: 10.2337/diacare.24.9.1685-a. No abstract available. PubMed 11522720 ↗
  • Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P, Verlato G. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000 Jan;23(1):45-50. doi: 10.2337/diacare.23.1.45. PubMed 10857967 ↗
  • White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008 Dec;126(12):1707-15. doi: 10.1001/archopht.126.12.1707. PubMed 19064853 ↗
  • Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications. 2011 Sep-Oct;25(5):332-8. doi: 10.1016/j.jdiacomp.2011.06.004. Epub 2011 Aug 2. PubMed 21813293 ↗
  • Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. Clin Exp Pharmacol Physiol. 2010 May;37(5-6):564-8. doi: 10.1111/j.1440-1681.2010.05361.x. Epub 2010 Jan 17. PubMed 20082624 ↗
  • Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet Med. 2006 May;23(5):522-8. doi: 10.1111/j.1464-5491.2006.01839.x. PubMed 16681561 ↗
  • Mu P, Lu H, Zhang G, Chen Y, Fu J, Wang M, Shu J, Zeng L. Comparison of fasting capillary glucose variability between insulin glargine and NPH. Diabetes Res Clin Pract. 2011 Jan;91(1):e4-7. doi: 10.1016/j.diabres.2010.09.026. PubMed 20970870 ↗
  • Li S, Tang X, Luo Y, Wu B, Huang Z, Li Z, Peng L, Ling Y, Zhu J, Zhong J, Liu J, Chen Y. Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study. Cardiovasc Diabetol. 2020 Sep 25;19(1):146. doi: 10.1186/s12933-020-01126-0. PubMed 32977802 ↗
  • Tang X, Zhong J, Zhang H, Luo Y, Liu X, Peng L, Zhang Y, Qian X, Jiang B, Liu J, Li S, Chen Y. Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes. Cardiovasc Diabetol. 2019 Apr 16;18(1):50. doi: 10.1186/s12933-019-0854-9. PubMed 30992008 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jul 2023 and a completion of Jul 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2015
First posted
Oct 27, 2015
Start
Jul 2015
Primary completionEst.
Jul 2023
CompletionEst.
Jul 2025
Last update
Oct 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02587741
Responsible party
Yanming Chen (Professor of Internal Medicine, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Oct 27, 2015
Start date
Jul 2015
Primary completion
Jul 2023 (estimated)
Completion
Jul 2025 (estimated)
Last update
Oct 27, 2015

Study contacts

Chen Yanming, Doctor
Contact
1211587508@qq.com
+8618922102818
Zhu Bilian, Master
Contact
bilianzhu@qq.com
+8613580364394
Mu panwei, Doctor
principal investigator · Employ

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Insulin Glargine

Start the discussion